vs
CareDx, Inc.（CDNA）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是CareDx, Inc.的1.5倍（$179.7M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -29.5%，领先31.8%），CareDx, Inc.同比增速更快（39.0% vs 35.7%），CareDx, Inc.自由现金流更多（$514.0K vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
CDNA vs RKLB — 直观对比
营收规模更大
RKLB
是对方的1.5倍
$117.7M
营收增速更快
CDNA
高出3.3%
35.7%
净利率更高
CDNA
高出31.8%
-29.5%
自由现金流更多
CDNA
多$114.7M
$-114.2M
两年增速更快
RKLB
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $179.7M |
| 净利润 | $2.8M | $-52.9M |
| 毛利率 | — | 38.0% |
| 营业利润率 | 1.0% | -28.4% |
| 净利率 | 2.4% | -29.5% |
| 营收同比 | 39.0% | 35.7% |
| 净利润同比 | — | -1.1% |
| 每股收益（稀释后） | $0.05 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARKLB
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $179.7M | ||
| Q3 25 | $100.1M | $155.1M | ||
| Q2 25 | $86.7M | $144.5M | ||
| Q1 25 | $84.7M | $122.6M | ||
| Q4 24 | $86.6M | $132.4M | ||
| Q3 24 | $82.9M | $104.8M | ||
| Q2 24 | $92.3M | $106.3M |
净利润CDNARKLB
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-52.9M | ||
| Q3 25 | $1.7M | $-18.3M | ||
| Q2 25 | $-8.6M | $-66.4M | ||
| Q1 25 | $-10.4M | $-60.6M | ||
| Q4 24 | $87.7M | $-52.3M | ||
| Q3 24 | $-10.6M | $-51.9M | ||
| Q2 24 | $-4.6M | $-41.6M |
毛利率CDNARKLB
| Q1 26 | — | — | ||
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.6% |
营业利润率CDNARKLB
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | -28.4% | ||
| Q3 25 | -0.2% | -38.0% | ||
| Q2 25 | -12.8% | -41.3% | ||
| Q1 25 | -15.8% | -48.3% | ||
| Q4 24 | 97.5% | -38.9% | ||
| Q3 24 | -16.6% | -49.5% | ||
| Q2 24 | -7.9% | -40.7% |
净利率CDNARKLB
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -29.5% | ||
| Q3 25 | 1.7% | -11.8% | ||
| Q2 25 | -9.9% | -46.0% | ||
| Q1 25 | -12.2% | -49.5% | ||
| Q4 24 | 101.3% | -39.5% | ||
| Q3 24 | -12.8% | -49.6% | ||
| Q2 24 | -5.0% | -39.2% |
每股收益（稀释后）CDNARKLB
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $-0.09 | ||
| Q3 25 | $0.03 | $-0.03 | ||
| Q2 25 | $-0.16 | $-0.13 | ||
| Q1 25 | $-0.19 | $-0.12 | ||
| Q4 24 | $1.60 | $-0.11 | ||
| Q3 24 | $-0.20 | $-0.10 | ||
| Q2 24 | $-0.09 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | — | $1.7B |
| 总资产 | $411.1M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资CDNARKLB
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $1.0B | ||
| Q3 25 | $194.2M | $976.7M | ||
| Q2 25 | $186.3M | $688.1M | ||
| Q1 25 | $230.9M | $428.4M | ||
| Q4 24 | $260.7M | $419.0M | ||
| Q3 24 | $240.9M | $442.4M | ||
| Q2 24 | $228.9M | $496.8M |
总债务CDNARKLB
| Q1 26 | — | — | ||
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | $0 | $61.2M | ||
| Q2 24 | $0 | $64.2M |
股东权益CDNARKLB
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $1.7B | ||
| Q3 25 | $311.1M | $1.3B | ||
| Q2 25 | $327.4M | $688.5M | ||
| Q1 25 | $379.3M | $431.3M | ||
| Q4 24 | $378.4M | $382.5M | ||
| Q3 24 | $273.2M | $419.8M | ||
| Q2 24 | $264.7M | $455.2M |
总资产CDNARKLB
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $2.3B | ||
| Q3 25 | $432.3M | $2.2B | ||
| Q2 25 | $444.3M | $1.6B | ||
| Q1 25 | $489.6M | $1.3B | ||
| Q4 24 | $491.1M | $1.2B | ||
| Q3 24 | $477.0M | $1.2B | ||
| Q2 24 | $466.8M | $1.2B |
负债/权益比CDNARKLB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | 0.00× | 0.15× | ||
| Q2 24 | 0.00× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $-114.2M |
| 自由现金流率自由现金流/营收 | 0.4% | -63.6% |
| 资本支出强度资本支出/营收 | — | 27.6% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-321.8M |
8季度趋势，按日历期对齐
经营现金流CDNARKLB
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $-64.5M | ||
| Q3 25 | $37.4M | $-23.5M | ||
| Q2 25 | $9.9M | $-23.2M | ||
| Q1 25 | $-26.6M | $-54.2M | ||
| Q4 24 | $21.9M | $-2.4M | ||
| Q3 24 | $12.5M | $-30.9M | ||
| Q2 24 | $18.9M | $-13.0M |
自由现金流CDNARKLB
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-114.2M | ||
| Q3 25 | — | $-69.4M | ||
| Q2 25 | — | $-55.3M | ||
| Q1 25 | — | $-82.9M | ||
| Q4 24 | — | $-23.9M | ||
| Q3 24 | — | $-41.9M | ||
| Q2 24 | — | $-28.3M |
自由现金流率CDNARKLB
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -44.8% | ||
| Q2 25 | — | -38.3% | ||
| Q1 25 | — | -67.6% | ||
| Q4 24 | — | -18.1% | ||
| Q3 24 | — | -40.0% | ||
| Q2 24 | — | -26.7% |
资本支出强度CDNARKLB
| Q1 26 | — | — | ||
| Q4 25 | — | 27.6% | ||
| Q3 25 | — | 29.6% | ||
| Q2 25 | — | 22.2% | ||
| Q1 25 | — | 23.4% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 10.5% | ||
| Q2 24 | — | 14.4% |
现金转化率CDNARKLB
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
